Kyowa Kirin Head Sees Major Global Status For Newly Formed Biotech
This article was originally published in PharmAsia News
Executive Summary
Kyowa Kirin intends to go head to head in 2012 with the world's largest biotechnology companies, the president of the recently formed Japanese company says. Created through a merger of Kyowa Hakko Kogyo and Kirin Pharma last October, the company is banking on its advanced antibody technologies to help it catch up with big biotechs such as Amgen and Genentech of the United States. The key technologies in that effort are Potelligent and Complegent, already licensed to 10 drug makers, including major multinationals. Kyowa Kirin President Yuzuru Matsuda anticipates blockbuster status for drugs derived from the technologies, which would lead to a "rain fall" of royalties for the company. (Click here for more - a subscription may be required